Charting the Epigenomic Landscape of Advanced Prostate Cancer in Human Tissue

About Charting the Epigenomic Landscape of Advanced Prostate Cancer in Human Tissue
  • The androgen receptor (AR) is the primary driver of prostate cancer and regulates the expression of genes required for tumor growth and survival. Understanding the differential effects of the AR in normal prostate vs. prostate cancer will enable discovery of new pathways involved in the development of malignancy.
  • Dr. Matthew Freeman and team will map the AR “cistrome” – the genes regulated by AR, in clinical specimens from prostate cancer patients.
  • The AR cistrome will be examined during the progression of prostate cancer from early stage tumors to those that have acquired resistance to the AR-targeting therapies abiraterone and enzalutamide. Genes involved in disease progression and acquired treatment-resistance will be discovered.
  • The precise role of other proteins that cooperate with AR to regulate target genes during the progression of prostate cancer will be investigated.
  • These studies will lead to the discovery of new predictive biomarkers for optimal therapy and potential drug targets to prevent prostate cancer progression and drug-resistance.

What this means for patients: The androgen receptor (AR) is the primary driver of prostate cancer and acts by turning on expression of many genes involved in tumor growth and survival. This project will define the genes regulated by AR and its cancer-promoting partners that are important in disease progression and treatment-resistance. These discoveries may lead to the development of new therapies and predictive biomarkers to optimize treatment for prostate cancer patients.

 

Principal Investigator:

Matthew Freedman, MD (Broad Institute of MIT and Harvard)

Co-investigators:

Mark Pomerantz, MD (Harvard: Dana-Farber Cancer Institute), Myles Brown, MD (Harvard: Dana-Farber Cancer Institute), Henry Long, PhD (Harvard: Dana-Farber Cancer Institute), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute), Rana McKay, MD (Harvard: Dana-Farber Cancer Institute), Zoltan Szallasi, MD (Harvard: Boston Children’s Hospital), Fugen Li, PhD (Harvard: Dana-Farber Cancer Institute), Michaela Bowden, PhD (Harvard: Dana-Farber Cancer Institute), Massimo Loda, MD (Harvard: Dana-Farber Cancer Institute).